Bernstein·2026-11-02CompanyMarket-Perform$756 → $812▲Regeneron Pharmaceuticals Inc (REGN.US) Regeneron 3Q26: Strong quarter; growth driven by Dupixent and Eylea
Morgan Stanley·2026-10-30CompanyEqual-weight$779 → $855▲Regeneron Pharmaceuticals Inc. (REGN.US): Robust Dupi growth continues; Cemdi for MG up next
Citi·2026-10-30CompanyNeutral$740 → $825▲Regeneron Pharmaceuticals Inc (REGN.US) Final thoughts on 3Q; Good execution supports higher estimates; pipeline validation remains key
Goldman Sachs·2026-10-23CompanyBuy$968Regeneron Pharmaceuticals Inc. (REGN.US): 3Q earnings preview: Focus is on pipeline and commercial opportunities therein, and BD strategy
BofA Securities·2026-10-12CompanyBuy$891 → $908▲Regeneron Pharmaceuticals Inc. (REGN.US): 3Q preview: Retinal specialist survey supports continued growth of Eylea HD
Goldman Sachs·2026-09-18SectorGlobal Healthcare: Pharmaceuticals: China Biopharma: Continued momentum amidst emerging policy dynamics